CN104223094A - 具有益生菌的营养组合物 - Google Patents
具有益生菌的营养组合物 Download PDFInfo
- Publication number
- CN104223094A CN104223094A CN201410366993.4A CN201410366993A CN104223094A CN 104223094 A CN104223094 A CN 104223094A CN 201410366993 A CN201410366993 A CN 201410366993A CN 104223094 A CN104223094 A CN 104223094A
- Authority
- CN
- China
- Prior art keywords
- composition
- sugared
- bifidobacterium
- lactobacillus
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 136
- 235000016709 nutrition Nutrition 0.000 title claims 2
- 239000006041 probiotic Substances 0.000 title description 9
- 235000018291 probiotics Nutrition 0.000 title description 9
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 41
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 16
- 208000030172 endocrine system disease Diseases 0.000 claims abstract description 7
- 208000026278 immune system disease Diseases 0.000 claims abstract description 7
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 5
- 208000010643 digestive system disease Diseases 0.000 claims abstract description 5
- 208000018685 gastrointestinal system disease Diseases 0.000 claims abstract description 5
- 241000186660 Lactobacillus Species 0.000 claims description 69
- 229940039696 lactobacillus Drugs 0.000 claims description 62
- 235000000346 sugar Nutrition 0.000 claims description 61
- 241000186000 Bifidobacterium Species 0.000 claims description 48
- 210000000481 breast Anatomy 0.000 claims description 36
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 claims description 30
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 28
- 150000002772 monosaccharides Chemical group 0.000 claims description 25
- 229930091371 Fructose Natural products 0.000 claims description 23
- 239000005715 Fructose Substances 0.000 claims description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 23
- 239000008103 glucose Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 238000006116 polymerization reaction Methods 0.000 claims description 20
- 235000018102 proteins Nutrition 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 235000014633 carbohydrates Nutrition 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 11
- 210000000936 intestine Anatomy 0.000 claims description 9
- 206010012735 Diarrhoea Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 210000002784 stomach Anatomy 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
- 235000020256 human milk Nutrition 0.000 claims description 7
- 210000004251 human milk Anatomy 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims description 5
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 5
- 206010010774 Constipation Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 230000001332 colony forming effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 238000010606 normalization Methods 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 3
- 206010016946 Food allergy Diseases 0.000 claims description 3
- 208000007683 Pediatric Obesity Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 241000186605 Lactobacillus paracasei Species 0.000 abstract description 3
- 208000017701 Endocrine disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 235000013336 milk Nutrition 0.000 description 15
- 239000008267 milk Substances 0.000 description 15
- 210000004080 milk Anatomy 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 13
- 235000013350 formula milk Nutrition 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 229940118199 levulan Drugs 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 9
- 239000002689 soil Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 230000000529 probiotic effect Effects 0.000 description 8
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 7
- 240000001046 Lactobacillus acidophilus Species 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- 241001608472 Bifidobacterium longum Species 0.000 description 5
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 5
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 5
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 5
- 244000199866 Lactobacillus casei Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 5
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 5
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000036428 airway hyperreactivity Effects 0.000 description 4
- 229940004120 bifidobacterium infantis Drugs 0.000 description 4
- 229940009291 bifidobacterium longum Drugs 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- -1 glucose monosaccharide Chemical class 0.000 description 4
- 229940017800 lactobacillus casei Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 229920002670 Fructan Polymers 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000186840 Lactobacillus fermentum Species 0.000 description 3
- 241000186604 Lactobacillus reuteri Species 0.000 description 3
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 3
- 201000010859 Milk allergy Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 description 3
- 235000021125 infant nutrition Nutrition 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 108010084695 Pea Proteins Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 229920000377 Sinistrin Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000019702 pea protein Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108010042243 Aptamil Proteins 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 1
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000157 polyfructose Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pediatric Medicine (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
组合物,包含短双歧杆菌,不可消化的糖A和不可消化的糖B,其可选组合有副干酪乳杆菌,以及所述组合物在治疗和/或预防胃肠疾病、免疫疾病和/内分泌疾病中的用途。
Description
本申请是2006年2月28日提交的题为“具有益生菌的营养组合物”的中国专利申请200680006368.2的分案申请。
技术领域
本发明涉及包含至少两种不同的不可消化的益生素糖(prebiotic saccharide)和至少一种益生菌(probiotic bacterium)。所述营养组合物尤其适合喂养婴儿。
技术背景
婴儿在出生时缺乏肠道菌群。作为在出生过程中与母亲的接触以及随后用母乳或配方奶喂养的结果,肠道菌群快速发展。在肠道菌群发展的过程中,其仍然是不成熟的并且其平衡是脆弱的。母乳喂养的婴儿与配方奶喂养的婴儿相比较少出现感染或疾病。因此,与配方奶喂养的婴儿相比,母乳喂养的婴儿的胃肠感染的发病率和持续期都较低,较少出现特应性疾病诸如过敏症,湿疹,较少的绞痛和痉挛,以及较少的便秘。生命后期中出现的疾病,诸如幼儿肥胖,糖尿病以及哮喘与生命早期阶段喂养类型也相关,母乳喂养的婴儿具有优势。
通常,母乳喂养的婴儿的肠道菌群主要由双歧杆菌属(Bifidobacteria)和乳杆菌属(Lactobacilli)组成。母乳含有母乳寡糖,其是婴儿肠道中双歧杆菌的生长因子。配方奶喂养的婴儿中的菌群更加多样化并且通常含有更多的拟杆菌(Bacteroides),梭菌(Clostridium)和肠杆菌(Enterobacteriaceae)。配方奶喂养的婴儿具有的双歧杆菌的数量是母乳喂养的婴儿所具有的大约十分之一到大约三分之二。双歧杆菌和乳杆菌被认为对于维持平衡良好的肠道小型生物群中非常重要,并且认为双歧杆菌和乳杆菌具有多种健康促进效应,包括预防和/或治疗腹泻和肠道感染。此外,已经显示、双歧杆菌和乳杆菌在宿主免疫***中起作用。
目前的方法是在总体上促进双歧杆菌,即在属的水平。双歧杆菌属由多种不同种组成,其在代谢、酶活性、寡-和多糖利用,细胞壁组成,以及与宿主的免疫***的相互作用等方面不同。因此,不是每种双歧杆菌都对婴儿具有相同的功能影响。青春双歧杆菌(B.adolescentis)在成人以及过敏性婴儿的菌群中更加常见,在健康婴儿的粪便中较少。动物双歧杆菌(B.animalis)/乳酸双歧杆菌(B.lactis)并非天然存在人中。在健康婴儿中,双歧杆菌菌群主要由婴儿双歧杆菌(B.infantis),短双歧杆菌(B.breve)和长双歧杆菌(B.longum)组成。本发明的主要目的在于在配方奶喂养的婴儿中获得这样的菌群,其在双歧杆菌水平上与母乳喂养的婴儿中的菌群相似。
EP1105002描述了两种不同的不可消化的碳水化合物在改善肠菌群中的用途。所述碳水化合物具体包括半乳-寡糖(galacto-oligosaccharide)以及果-聚糖(fructo-polysaccharide)。
发明内容
本发明人发现了对人类婴儿喂以不同不可消化的单糖的组合增加粪便中的双歧杆菌水平并在种的水平调节肠道中的双歧杆菌群体达到类似在母乳喂养的婴儿中观察到的水平,即低水平的小链双歧杆菌(B.catenulatum),假链双歧杆菌(B.pseudocatenulatum),和青春双歧杆菌(青春双歧杆菌)。但是,发现短双歧杆菌与母乳喂养的婴儿的情况相比相对较低。
因此,一方面,本发明提供组合物,其包含不可消化的单糖A和不可消化的单糖B以及短双歧杆菌。所述组合物优选用于平衡双歧杆菌在配方奶喂养的婴儿的胃肠道中的分布。
另一方面,还发现对婴儿喂以含有不同不可消化的糖的组合的配方奶增加粪便中乳杆菌水平并在种的水平调节肠道中的乳杆菌水平,使其达到与在母乳喂养的婴儿中观察到的水平相似的水平。但是,发现副干酪乳杆菌(Lactobacillus paracasei)(L.paracasei)的浓度与母乳喂养的婴儿相比相对较低。因此,本发明另一方面提供一种组合物,其包含短双歧杆菌和副干酪乳杆菌,优选与不可消化的糖A以及不可消化的糖B组合。发现这些细菌的群体在接受配方奶的婴儿的胃肠道中发育较差。因此,益生细菌的这种组合可优选用于喂养婴儿以及模拟母乳喂养的婴儿的肠道菌群。
附图说明
图1:气道高反应性的图,其显示为相对PenH(延长的暂停)相对于以下组的小鼠中的醋甲胆碱浓度的图,所述小鼠为接受短双歧杆菌、反式半乳寡糖(transgalacto-oligosaccharide)以及果聚糖(fructopolysaccharide)的组合的小鼠;以及接受盐水的小鼠对照组。
发明内容
本发明提供具有以下性质的组合物:粘度1-60mPa.s,热密度10-250kcal每100ml,包含短双歧杆菌,不可消化的糖A以及不可消化的糖B,其中:
a.不可消化的糖A的聚合度为2-200并且糖A的总单糖单位的至少60mol%是选自半乳糖,果糖或葡萄糖单糖的单糖;以及
b.不可消化的糖B的聚合度为2-200并且糖B的总单糖单位的至少60mol%是选自半乳糖,果糖或葡萄糖单糖的单糖;以及
其中
i)糖A中选自葡萄糖,果糖或半乳糖的至少一种单糖的百分比比糖B中相同单糖的百分比高至少40mol%;和/或
ii)糖A的至少一个糖苷键基于糖A的总糖苷键的百分比比糖B中相同糖苷键的百分比高至少40%;和/或
iii)糖A的聚合度比糖B的聚合度低至少5个单糖单位。
另一方面,本发明提供一种组合物,其包含5-16en.%蛋白质,30-60en.%脂肪,和25-75en.%碳水化合物,并包含短双歧杆菌以及副干酪乳杆菌。
另一方面,本发明提供本发明的组合物用于制备将非母乳喂养的或部分母乳喂养的婴儿胃肠道中的双歧杆菌和/或乳杆菌种类的群体正常化为母乳喂养的婴儿中的双歧杆菌和/或乳杆菌种类的群体的组合物中的用途。
本发明另一方面提供本发明的组合物在制备用于预防和/或治疗胃肠道疾病、免疫疾病和/或内分泌疾病,优选牛奶过敏症和/或感染的组合物中的用途。
粘度
本发明组合物的粘度为1-60mPa.s,优选1-20mPa.s,更优选1-10mPa.s,最优选1-6mPa.s。低粘度保证液体的适当给予,例如适宜地通过奶嘴的给予。该粘度也非常接近母乳的粘度。此外,低粘度导致正常胃排空以及更好的能量吸收,其对于需要能量用于最佳生长和发育的婴儿而言是必需的。本发明的组合物优选通过将粉末状的组合物与水混合来制备。通常婴儿配方奶以此种方式制备。本发明因此涉及包装的粉末组合物,其中所述包装提供将粉末与适宜量的液体混合的说明,由此产生粘度1-60mPas的液体组合物。
液体粘度利用Physica Rheometer MCR 300(Physica MesstechnikGmbH,Ostfilden,Germany)在20℃、剪切速率95s-1的条件下测定。
短双歧杆菌
短双歧杆菌是革兰氏阳性厌氧型分支棒状细菌。优选,本发明的短双歧杆菌与短双歧杆菌常规菌株ATCC 15700相比其16S rRNA具有至少95%的相同性,更优选至少97%相同性(Stackebrandt & Goebel,1994,Int.J.Syst.Bacteriol.44:846-849)。本发明所用双歧杆菌优选与短双歧杆菌探针杂交,并且利用本文下文所述的5’核酸酶测定法产生信号。
优选的短双歧杆菌菌株是分离自健康母乳喂养的婴儿的粪便的那些。通常,这些可商购得自乳酸细菌生产商,但是也可直接分离自粪便,经鉴定、定性并产生。根据优选实施方案,本发明的组合物含有至少一种选自下组的短双歧杆菌:短双歧杆菌Bb-03(Rhodia),短双歧杆菌M-16V(Morinaga),短双歧杆菌R0070(Institute Rosell,Lallemand),DSM 20091,或LMG 11613。最优选,所述短双歧杆菌是短双歧杆菌M-16V(Morinaga)。
本发明的组合物优选含102-1013集落形成单位(cfu)的短双歧杆菌/本发明组合物的每克干重,优选104-1012,更优选105-1010,最优选105-1x109cfu短双歧杆菌/本发明组合物的每克干重。
最优选,本发明的组合物含有104-1012,更优选105-1011,最优选107-5x1010集落形成单位(cfu)短双歧杆菌/每g糖A和B总量。
根据本发明短双歧杆菌的剂量优选以日剂量102-1013给药,更优选以105-1011,最优选以108-5x1010集落形成单位(cfu)给药。
不可消化的糖
本发明提供一种组合物,其包含不可消化的糖A和不可消化的糖B,在本文中分别称为糖A和糖B。糖A和糖B是不同的糖并具有不同的糖苷键和/或聚合度和/或单糖组成。
除了单糖半乳糖,果糖和葡萄糖,糖A和B可含有其他单糖单元诸如***糖,木糖和甘露糖,总量可达40%。但是优选,糖A和/或B的至少75%,更优选至少90%,或甚至至少98mol%的单糖单元总量是选自半乳糖,果糖或葡萄糖的单糖。优选α-连接的葡萄糖的相对量低于30%,具体低于15%。
本发明术语糖优选指不可消化的糖的混合物。本发明术语糖B优选指不可消化的糖的混合物。这是常识,因为利用具有例如一种链长度的糖非常昂贵。优选且常见地,所述混合物仅仅在主要单糖的数量上不同。当糖A和/或B是糖混合物,每种参数的平均值用于定义本发明。例如,如果糖A是各种糖的混合物,其中包含25wt.%Glu-Gal-Gal-Gal,25wt.%Glu-Gal-Gal和50wt.%Gal-Gal,平均单糖组合物是85.4%Gal和14.6%Glu。平均聚合度(DP)是2.75。
术语不可消化的糖指胃肠道中保持未消化并且不被吸收到达大肠的糖,即没有在人优选人婴儿的上消化道中消化的糖,例如没有被存在人肠道中的酸或酶消化。注意到可消化的糖不是糖A和B的一部分。因此,例如葡萄糖、果糖、半乳糖、蔗糖、乳糖和麦芽糊精被认为是可消化的。
优选糖A和B是水溶性的。根据L.Prosky et al,J.Assoc.Anal.Chem 71:1017-1023,1988所述的方法,水溶性糖至少50%是水溶性的。
优选实施方案中至少80wt.%的不可消化的糖A和B是可发酵的。术语“可发酵的”在本文指由胃肠道下半部分(例如结肠)中的微生物分解成小分子的能力,具体是短链脂肪酸和乳酸盐。不可消化的糖A和B的可发酵性优选通过Am.J.Clin.Nutr.53,1418-1424(1991)所述的方法确定。更优选的实施方案中,至少80wt.%的不可消化的糖A和B是益生素。“益生素(prebiotic)”定义为不可消化的食物成分,其选择性刺激一或多种细菌种类在结肠中的生长和/或活性,并由此有利地影响宿主(Gibson and Roberfroid,J.Nutr.125:1401-1412(1995))。
单糖组合物
糖A和B的全部单糖单元的至少60mol%,优选至少75mol%,更优选至少90mol%,最优选至少98mol%是选自半乳糖(gal),果糖(fru)或葡萄糖(glu)的单糖。根据本发明的优选实施方案,糖A中至少一种选自葡萄糖,果糖或半乳糖的单糖的百分比比糖B中的相同单糖的百分比高至少40mol%,优选至少50mol%,更优选至少75mol%,更优选至少90mol%。单糖的多样性增加刺激更广泛的有益肠细菌的群体。
优选糖A和B的至少50wt.%,优选至少75wt.%的累积重量是DP2-8的不可消化的糖。通过利用高小糖重量百分比的混合物,对乳酸细菌和双歧杆菌的可发酵性以及生长的刺激效应将增加。
糖中单糖的百分比可通过用糖中的各个单糖单元(例如葡萄糖)的量除以糖中的单糖单元总量再乘以100来简单计算。当糖是糖混合物的情况,每种单独的糖在糖混合物中的贡献必须被考虑在内。糖混合物的百分比可通过将所述混合物完全水解并测定每种单糖的摩尔百分比来简单地测定。
优选糖A含有至少40mol%半乳糖,更优选至少67mol%半乳糖,更优选至少75mol%半乳糖。优选糖B含有至少30mol%果糖,更优选至少67mol%果糖,更优选至少75wt.%果糖。
例如,在糖A是glu-(gal)n=2-7混合物且平均单糖组成为20mol%葡萄糖和80mol%半乳糖、并且糖B是glu-(fru)n=2-7和(fru)n2-7混合物且平均单糖组成为10mol%葡萄糖和90mol%果糖的情况下,区别是a)葡萄糖为10mol%;b)果糖为90mol%;c)半乳糖为80mol%。在该实例中半乳糖满足了这样的标准,即糖A中至少一种选自葡萄糖,果糖或半乳糖的单糖的百分比比糖B中相同单糖的百分比高至少40mol%。
聚合度
糖A和B的聚合度(DP)为2-200。优选糖A和B的累积重量的至少80wt.%,更优选至少95wt.%,最优选至少98wt.%的聚合度(DP)低于100,更优选低于60,最优选低于40。较低的DP优选降低粘度并增加不可消化的糖的可发酵性。优选糖A的至少50wt.%,优选至少75wt.%是DP 2-8的不可消化的糖。通过利用高小糖重量百分比的混合物,对乳酸细菌和双歧杆菌的可发酵性以及对其生长的刺激效应将得以增加。
根据本发明的优选实施方案,糖A的DP比糖B的聚合度低至少5个,优选至少10个,更优选至少15个单糖单元。使糖具有增加的聚合度降低渗透负荷,其对于婴儿营养有利并且提供对结肠最远端部分的肠道菌群的益生素刺激。
最优选,糖A的DP为2-15,更优选2-8。优选糖B的DP为8-100。DP不同的糖A和B具有相同或者稍微不同的单糖组成。如果糖A和B的DP不同而单糖组成相似,则糖A和糖B的平均DP的差异优选至少5,更优选至少10,更优选至少15。优选,糖A和B具有不同的单糖组成(见上文)以及不同的DP。
例如,如果糖A是平均DP4.5单糖单位的glu-frum=2-7和frum=2-6的混合物,并且糖B是平均DP为25个单糖单元的glu-frun=12-100,则平均DP差异为(25-4.5=)20.5。
糖苷键
本发明优选实施方案中,糖A的至少一个糖苷键基于糖A的总糖苷键的百分比比糖B中的相同的糖苷键的百分比高至少40%,优选至少50%,更优选至少75%。术语“糖苷键”在本发明指两个环状单糖的环通过消去水形成的C-O-C连接。糖苷键的密度增加刺激更广范围的有益细菌。
糖苷键的区别在于它们共价结合于单糖单元中不同编号的位置的碳原子,和/或它们形成α或β键。不可消化的糖中存在的不同糖苷键的实例是β(1,3),α(1,4),β(2,1),α(1,2),和β(1,4)键。
优选糖A中的糖苷键包含至少40%,更优选至少75%的β(1,4)和/或β(1,6)糖苷键。糖B中的糖苷键优选包含至少40%,更优选至少75%的β(2,1)糖苷键。
组合
具体优选的实施方案中,本发明的糖A和B在选自糖苷键、聚合度或单糖组成中的至少两个方面不同。优选,本发明的糖A和B的聚合度不同并且在选自糖苷键或单糖组成的至少一个方面不同。更优选,本发明的糖A和B的聚合度和单糖组成不同。最优选所有三个方面均不同。给药不同大小,不同“级别”,和/或“结构”的糖的混合物协同性刺激肠道菌群。其有利地影响健康。
糖A和B的浓度
本发明的组合物优选包含至少5mg糖A每100ml,优选至少50mg糖A每100ml,更优选至少0.1g糖A每100ml,最优选至少0.5g糖A每100ml。优选本发明的组合物包含不超过10g糖A每100ml,优选不超过2.0g每100ml。本发明的组合物优选包含至少5mg糖B每100ml,优选至少10mg糖B每100ml,更优选至少25mg糖B每100ml,最优选至少50mg糖B每100ml。优选本发明的组合物包含不超过10g糖B每100ml,优选不超过1g每100ml。
糖A和B的重量比优选0.01-100,更优选0.5-100,更优选4-100,最优选24-99。高重量比在糖A具有低DP且糖B具有相对高DP的情况中尤其有利。其保证可渗透性和可发酵性之间的最佳平衡。
基于本发明组合物中不可消化的糖的总重量,糖A和糖B优选包含5-100wt.%,更优选50-100wt.%不可消化的糖。
本发明的不可消化的糖A和B优选以日剂量0.1-30g(糖A重量+糖B重量),更优选0.5-15g,更优选3-10g给药。
优选的糖
不可消化的糖A优选选自β-半乳寡糖,α-半乳寡糖或(***(arabino)-)半乳聚糖。根据更加优选的实施方案,糖A是β-半乳寡糖,更优选反式半乳寡糖(TOS)。优选糖A包含β-半乳寡糖,其具有β(1,4)和/或β(1,6)糖苷键以及末端葡萄糖。TOS例如可以商品名GOS(Borculo Domo Ingredients,Zwolle,Netherlands)购得。
不可消化的糖B优选选自果聚糖或果糖寡糖。术语果聚糖(frctopolysaccharide),多聚果糖(polyfructose),多聚果聚糖(polyfructan)和聚果糖(fructan)在本文可互换使用,并且指包含β-连接的果糖单元的多糖,其优选通过β(2,1)和/或β(2,6)糖苷键连接。最优选,果聚糖含有末端β(2,1)糖苷键连接的葡萄糖。最优选,果聚糖含有至少7β-连接的果糖单元。另一优选实施方案中,胰岛素用作糖B。胰岛素是这种类型的果聚糖,其中至少75%的糖苷键是β(2,1)键。通常,胰岛素的平均链长度为8-60个单糖单元。适宜用于组合物的果聚糖可以商品名例如HP(Orafti)购得。
另一优选实施方案中,糖B果聚寡糖(fructooligosaccharide)。果聚寡糖是包含β连接的果糖单元的糖,其优选通过β(2,1)和/或β(2,6)糖苷键连接。果聚寡糖优选含有在还原末端由β(2,1)糖苷键连接的葡萄糖。最优选,所述果聚寡糖含有2-6个β-连接的果糖单元。果聚寡糖的适宜来源是(Orafti),或Actilight(Beghin-Meiji)。
副干酪乳杆菌
优选实施方案中,本发明的组合物包含副干酪乳杆菌。发现该细菌以有限的量存在非母乳喂养的婴儿中。因此,给药包含不可消化的糖A,不可消化的糖B,短双歧杆菌,和副干酪乳杆菌的组合物使得双歧杆菌在种的水平的正常化成为可能,也使得乳杆菌群体正常化到等同于母乳喂养婴儿的胃肠道中的水平成为可能。这是重要的,因为不同乳杆菌种类对宿主的影响不同。例如,保加利亚乳杆菌(L.delbrueckii)形成D-乳酸盐,其导致不成熟婴儿中的酸中毒,而副干酪乳杆菌形成L-乳酸盐。
优选本发明的乳杆菌菌株的16S rRNA序列与副干酪乳杆菌的典型菌株ATCC25032(Stackebrandt & Goebel,1994,Int.J.Syst.Bacteriol.44:846-849)相比具有至少95,更优选至少97%的序列相同性。本发明所用的乳杆菌优选与副干酪乳杆菌探针杂交,并且利用本文进一步描述的5’核酸酶测定法时产生信号。
优选的副干酪乳杆菌菌株是分离自健康母乳喂养的婴儿的粪便的那些。数种副干酪乳杆菌菌株可购自乳酸细菌生产商,但是它们也可直接从粪便分离,鉴定,定性并制备。根据优选的实施方案,本发明的组合物至少含有选自副干酪乳杆菌F19(Arla,Sweden),副干酪乳杆菌LAFTI L26(DSM Food Specialties,the Netherlands)和副干酪乳杆菌CRL431(Chr.Hansen,Denmark),LMG12165和LMG11407组成的组的副干酪乳杆菌。
本发明的组合物优选含有102-1013集落形成单位(cfu)的副干酪乳杆菌/本发明组合物的每克干重,优选104-1012,更优选105-1010,最优选105-1x109cfu副干酪乳杆菌/每克干重组合物。
最优选,本发明的组合物含有104-1012,更优选105-1011,最优选107-5x1010集落形成单位(cfu)的副干酪乳杆菌/每g糖A和B总重。
本发明的副干酪乳杆菌优选以日剂量102-1013,更优选105-1011,最优选108-5x1010集落形成单位(cfu)给药。
益生组合物(Combiotics)
另一方面,本发明提供这样的组合物,其包含5-16en.%的蛋白质,30-60en.%的脂肪,25-75en.%的碳水化合物,并包含短双歧杆菌和副干酪乳杆菌。给药这些细菌的组合据信刺激婴儿的胃肠道健康。本发明中描述关于包含糖A和B以及双歧杆菌的组合物的优选组合物特征、细菌种类和医学指征等同地应用于含有短双歧杆菌和副干酪乳杆菌的组合物。本发明中所述的糖A和/或糖B可优选地与短双歧杆菌和副干酪乳杆菌组合。如果副干酪乳杆菌存在于本发明的组合物中,单一类型的不可消化的糖足以获得所需的效果。另一方面,如果副干酪乳杆菌不存在,本发明具体涉及包含重量比为95:5-99:1的糖A和糖B的组合物。
除了短双歧杆菌和/或副干酪乳杆菌,其它微生物也可存在,但是没有获得实质性的进一步改善。所述其他微生物可包括其他双歧杆菌或其他乳杆菌或其他乳酸细菌。优选的双歧杆菌是长双歧杆菌和/或婴儿双歧杆菌。优选的乳杆菌是干酪乳杆菌(L.casei)和/或嗜酸性乳杆菌(L.acidophilus)。
常量营养素
本发明的组合物优选含有脂肪、碳水化合物和蛋白质。
优选本发明的组合物含有可消化的碳水化合物,其选自以下物质组成的组:麦芽糊精,淀粉,乳糖,麦芽糖,葡萄糖,果糖,和蔗糖。优选本发明的组合物含有乳糖。优选至少35wt.%,更优选至少50wt.%,最优选至少75wt.%的可消化性碳水化合物是乳糖。在液体形式中时,本发明的组合物优选包含6-19g可消化的碳水化合物每100ml,更优选6-10g每100ml。
优选10%-80%的总能量含量本发明的组合物通过可消化的碳水化合物提供。最优选,本发明的组合物含有25-75en.%碳水化合物。En.%是能量百分比的缩写,代表每种组成成分对制备物的总热量值的贡献的相对量。热量值由可消化的碳水化合物、蛋白质和脂肪提供。
常见的用于液体来源的组分包括动物油,植物油和微生物发酵油。脂肪是重要的能量来源并且对于婴儿的正常发育来讲非常重要。本发明优选含有亚麻酸(LA;omega6脂肪酸)和α-亚麻酸(ALA;omega3脂肪酸)。所述组合物优选包含0.3-1.5g LA每100ml,0.05-5g ALA每100ml。LA/ALA重量比优选5-15。优选本发明的组合物包含长链多不饱和脂肪酸(LC PUFA),更优选二十碳五烯酸(EPA)和/或二十二碳六烯酸(DHA)。优选实施方案中,所述组合物包含花生四烯酸(ARA)。优选所述组合物包含1-25mg,更优选4-15mg DHA每100ml。优选所述组合物包含2-50mg,更优选6-30mg ARA每100ml。LC-PUFA的存在有利地影响乳杆菌和/或双歧杆菌尤其是副干酪乳杆菌的建群。本发明的组合物优选包含30-60en.%脂肪,更优选39-50en.%脂肪。所述组合物优选包含2.1-6.5g脂肪每100ml。
优选本发明的组合物包含5-16en.%,更优选8-12en.%的蛋白质。优选本发明的组合物包含选自下组的蛋白质:酪蛋白,乳清蛋白,脱脂奶,大豆蛋白,豌豆蛋白质(pea protein),胶原蛋白,大米蛋白质(rice protein)和/或玉米蛋白质(corn protein)。优选至少25wt.%,更优选至少50wt.%,最优选至少90wt.%本发明的组合物的总蛋白通过水解的蛋白质和/或游离氨基酸来提供。蛋白水解物和/或有利氨基酸的利用降低过敏症的风险,具体是牛奶过敏症的风险。如果组合物是液体形式,优选其包含1.0-6.0g,更优选1.0-2.5g蛋白质每100ml。
本发明的组合物优选是液体。大便无规律(例如大便干硬,大便量不足,腹泻)是许多婴儿和接受液体食物的患者的主要问题。因此,本发明的组合物优选渗量(osmolality)为50-500mOsm/kg,更优选100-400mOsm/kg。具有所述的渗量的本发明的组合物特别适合用于治疗和/或预防腹泻。
同样重要的是本发明的组合物不具有过高的热密度,但是仍提供足够的热量来喂养受试者。因此,优选液体食物的热密度为10-250kcal每100ml,更优选50-90kcal/ml,最优选60-71kcal每100ml。最佳热密度也对腹泻的出现减少有贡献。
本发明的组合物优选包含矿物质,微量元素和维生素,胆碱,牛磺酸,肉碱,肌醇和/或其混合物。优选本发明的组合物含有牛磺酸,其减少哮喘症状(Adv.Exp.Med.Biol.2003526:403-10)。牛磺酸与本发明组合物中的组分协同作用。优选本发明的组合物包含核苷酸。最优选,所述组合物包含胞嘧啶5’-单磷酸盐,尿嘧啶5’-单磷酸盐,腺嘌呤5’-单磷酸盐,鸟嘌呤5’-单磷酸盐,以及肌苷5’-单磷酸盐。优选所述组合物包含0.75-10,更优选1.5-5mg核苷酸每100ml。核苷酸的存在有利地支持了双歧杆菌和乳杆菌,具体是短双歧杆菌和/或副干酪乳杆菌的存活和生长。优选本发明的组合物含有有机酸,香料和/或着色剂。
应用
已经发现本发明的组合物具体可用作婴儿营养物。所述组合物尤其适合根据母乳喂养的婴儿中的种类分布正常化在非或部分母乳喂养的婴儿的胃肠道中的双歧杆菌和/或乳杆菌群体,尤其是在早产儿、足月儿以及处于固体食物过渡期的婴儿中的那些。因此,本发明提供向人婴儿提供营养元素的方法,所述方法包括向婴儿提供本发明的组合物。优选,所述婴儿的年龄为0-36个月,更优选0-18个月,最优选0-12个月。
胃肠菌群对对于疾病诸如胃肠疾病、免疫疾病和/或内分泌疾病等具有重要影响。因此,另一方面,所述组合物可有利地用于制备用于预防和/或治疗胃肠疾病、免疫疾病和/或内分泌疾病的药物。尤其是过敏症(allergy),过敏性鼻炎(allergic rhinitis),食物超敏反应(foodhypersensitivity),异位性皮炎(atopic dermatitis),湿疹(eczema),哮喘(asthma),腹泻(diarrhoea),肠道炎症(intestinal inflammation),感染(infection),便秘(constipation),肠痉挛(intestinal cramp),绞痛(colic),幼儿肥胖症(childhood obesity),和/或糖尿病(diabetes)可适宜地利用本发明的组合物治疗。优选实施方案中,本发明提供用于治疗和/或与预防过敏症和/或感染的方法。本发明的组合物可有利地用于制备用于预防和/或治疗婴儿中的胃肠疾病、免疫疾病和/或内分泌疾病的药物。这些疾病的发病率降低是由于优化的菌群,具体是优化的双歧杆菌群体和/或优化的乳杆菌群体。本发明具体提供利用本发明的组合物制备用于预防和/或治疗牛奶过敏症和/或感染的药物。
实施例
实施例1:临床研究
该研究中,检测含有反式半乳寡糖和聚果糖的婴儿营养素对肠道双歧杆菌和乳杆菌的影响。如WO2005/039319所述进行所述研究并分析粪便样品。
婴儿被随机分入两个治疗组之一:一组(SF-组)接受标准婴儿配方奶I(Aptamil 1Milupa);一组(GFSF-组)接受补充有0.72g/100ml反式半乳-寡糖(GOS,VivinalTM(Borculo Domo Ingredients,Netherlands)和0.08g/100ml聚果糖(inulin,Raftilin HP,Orafti,Belgium)的标准配方奶。母乳喂养婴儿组包含在参照组(HMF组)中。
粪便样品中的不同双歧杆菌和乳杆菌的相对量通过双链体5’核酸酶测定法来测定。如WO2005/039319针对属于双栖杆菌的菌种设计并验证探针和引物,并针对乳杆菌设计并验证探针和引物。乳杆菌的探针和引物显示于表1。F是前向引物,R是反向引物,P是探针。表2显示用于对乳杆菌进行的双链体5’核酸酶测定法中的最终的最佳引物和探针浓度。双歧杆菌的总量也借助于FISH如前所述测定(Langendijk et al.1995Appl.Environ.Microbiol.61:3069-75.)测定。
表1:用于5’核酸酶测定法中的设计的引物和探针
*探针和引物来自Nadkarni et al,2002,Microbiology148:257-266。
表2:用于不同双链体5’核酸酶测定法中的优化的终引物和探针浓度
结果:
HMF,SF,和GFSF组中双歧杆菌占总细菌的百分比分别为75,47,和68%,喂养6个月后。乳杆菌的量分别为3.9,0.4,和4.2%。GFSF和SF组之间的差异在统计学上具有显著性。
表3中,显示了双歧杆菌相对于双歧杆菌的总量的百分比。
表3:6周的喂养之后,具体的双歧杆菌种类相对于母乳喂养婴儿以及接受标准配方奶(SF)或补充有TOS聚果糖(GFSF)的标准配方奶的婴儿的粪便(HMF)中的双歧杆菌总量的百分比。
a:研究期间明显降低
b:GFSF和SF组之间差异显著。
多种双歧杆菌存在三个不同的组中。此外,在母乳喂养的婴儿中以及接受GFSF的婴儿与接受标准配方奶的婴儿相反,其中的青春双歧杆菌明显降低。喂养6周之后,喂养SF的婴儿中的青春双歧杆菌明显高于喂养GFSF或母乳的婴儿中的情况。GFSF婴儿的粪便样品分析显示双歧杆菌菌群的变化很大,与母乳喂养的婴儿中的情况相似。与接受标准配方奶的婴儿的情况相比,母乳喂养的婴儿和接受GFSF的婴儿中也显示较少的链双歧杆菌(+假链双歧杆菌)。婴儿双歧杆菌和长双歧杆菌似乎在母乳喂养的婴儿以及接受标准配方奶(SF)或补充了益生素标准配方奶(GFSF)中为主要的。短双歧杆菌在所有三个组中也为主要的,但在接受母乳双歧杆菌的组中作为总双歧杆菌的a%在SF(4.9%)和GFSF(5.4%)组中更高(11.7%)。
表4中,显示了乳杆菌在以不同方式喂养的婴儿中的种类分布。
表4:在6周的喂养之后,具体的乳杆菌种类相对于母乳喂养的婴儿(HMF)和接受标准配方奶(SF)或TOS/果聚糖(GFSF)的标准配方奶的婴儿的粪便中的乳杆菌总数的百分比。
a:研究过程中明显增加
b:研究过程中明显降低
c:在GFSF和SF组中差异明显。
如可从表4中所见,多种乳杆菌存在母乳喂养的和标准配方奶喂养的婴儿中。然而,种类分布与在母乳喂养的和标准配方奶喂养的婴儿中的情况不相似。与其中观察到保加利亚乳杆菌增加的接受标准配方奶的婴儿相反,在母乳喂养的婴儿中可见保加利亚乳杆菌的降低。喂养6周后,在母乳喂养的婴儿中观察到嗜酸性乳杆菌,干酪乳杆菌和副干酪乳杆菌的明显增加,但是嗜酸性乳杆菌和副干酪乳杆菌的增加在配方奶喂养的婴儿中不明显。与母乳喂养的婴儿相比,标准配方奶喂养的婴儿倾向于具有相对高的发酵乳杆菌和L.reuteri浓度。令人吃惊的是,GFSF婴儿的粪便样品的分析显示与母乳喂养的婴儿相似的乳杆菌菌群的较大多样性。GFSF喂养的婴儿中种类分布与在母乳喂养的婴儿中观察到的情况非常相似。如在母乳喂养的婴儿中观察到的情况那样,GFSF喂养的婴儿具有相对降低的量的保加利亚乳杆菌,L.reuteri和发酵乳杆菌以及增加的量的嗜酸性乳杆菌,干酪乳杆菌和副干酪乳杆菌。GFSF喂养的婴儿中副干酪乳杆菌的相对量倾向低于母乳喂养的婴儿中的情况。
这些结果表明喂养不可消化的糖A和B的混合物导致双歧杆菌和乳杆菌的种类分布与在母乳喂养的婴儿中观察到的情况相似(即相对降低的青春双歧杆菌,链乳杆菌,保加利亚乳杆菌,发酵乳杆菌和/或L.reuteri以及相对增加的长双歧杆菌,婴儿双歧杆菌,短双歧杆菌,干酪乳杆菌,副干酪乳杆菌和/或嗜酸性乳杆菌),所述混合物中包含至少60,具体至少98mol%的一或多种选自半乳糖,果糖或葡萄糖的单糖单元,并且A和B在化学结构上不同。这些结果还表明给药不可消化的糖A和B的混合物与短双歧杆菌或短双歧杆菌加上副干酪乳杆菌的组合将恢复婴儿中的肠道菌群,使得就双歧杆菌和乳杆菌的分布而言,肠道菌群更加类似母乳喂养的婴儿中的情况,这将对婴儿中的肠道疾病、免疫疾病和/或内分泌疾病具有有益的治疗和/或预防效果。
实施例2:对过敏反应的影响
具体的无病原雄性BALB/c小鼠获自Charles River(Maastricht,the Netherlands)。可随意摄取食物和水,并且所用小鼠为6-9周龄。
小鼠通过用在100μl盐水中的吸附到2.25mg氢氧化铝上的10μg卵清蛋白或单独的盐水在第0天和第7天经两次i.p.注射敏感化。小鼠在第35,38和41天通过吸入卵清单白气溶胶在有机玻璃暴露小室中攻击20分钟。气溶胶可通过利用Pari LC Star雾化器(Pari respiratoryEquipment,Richmond,VA,USA)雾化卵清蛋白盐水溶液(10mg/ml)来产生。
小鼠每天口服1x109cfu短双歧杆菌和25mg反式半乳寡糖和果聚糖(9:1)混合物(实施例2的TOS/果聚糖混合物)通过填喂法(0.2ml,生理盐水)进行处理,在第28天开始直到实验结束(即第42天)。作为对照通过填喂法给药0.2ml生理盐水溶液。
对吸入的雾化醋甲胆碱的气道反应性在最后的气溶胶攻击14小时之后在清醒状态下的、不受限制的小鼠中利用整体体积描记法(plethysmography)(BUXCO,EMKA,Paris,France)测定。气道反应性表达为延长的暂停(PenH)。
结果:对气道高反应性的测定显示,与对照相比,接受短双歧杆菌,TOS和果聚糖的小鼠显示统计学降低的气道高反应性,表明降低的哮喘反应。图1中,气道高反应性作为相对PenH(延长的暂停)相对于接受短双歧杆菌+TOS/果聚糖混合物的组合的小鼠以及接受盐水的对照组小鼠中的醋甲胆碱浓度作图。图中相对PenH的值通过减去从没有被卵清单白敏感化的小鼠获得的空白值并相对于在醋甲胆碱的最高浓度获自对照组的值标准化获得。
实施例3
婴儿配方奶每100ml终产物粘度2.0±0.2mPa.s和:
Claims (17)
1.组合物,粘度为1-60mPa.s,热密度为10-250kcal每100ml,其包含短双歧杆菌,不可消化的糖A和不可消化的糖B,其中:
a.不可消化的糖A聚合度为2-200,并且糖A的总单糖单元的至少60mol%是选自半乳糖,果糖或葡萄糖的单糖;且
b.不可消化的糖B的聚合度为2-200,并且糖B的总单糖单元的至少60mol%是选自半乳糖,果糖或葡萄糖的单糖;且
其中
i)糖A中至少一种选自葡萄糖,果糖或半乳糖的单糖的百分比比糖B中相同单糖的百分比高至少40mol%;和/或
ii)糖A中至少一个糖苷键基于糖A中总糖苷键的百分比比糖B中相同糖苷键的百分比高至少40%;和/或
iii)糖A的聚合度比糖B的聚合度低至少5个单糖单元。
2.权利要求1的组合物,其粘度为1-6mPa.s。
3.权利要求1或2的组合物,其中糖A和糖B的重量比是24-99。
4.权利要求1或2的组合物,其中
i)糖A中至少一种选自葡萄糖,果糖或半乳糖的单糖的百分比比糖B中相同单糖的百分比高至少40mol%;和
ii)糖A的聚合度比糖B的聚合度低至少5个单糖单元。
5.权利要求1或2的组合物,还包括副干酪乳杆菌。
6.权利要求1或2的组合物,其中基于组分A中存在的糖链的单糖单元的总量,糖A的糖链包含至少67mol%半乳糖单元。
7.权利要求1或2的组合物,其中基于糖B中存在的单糖单元的总量,糖B的糖链包含至少67mol%果糖单元。
8.权利要求1或2的组合物,其中每g组合物干重包含102-1013集落形成单位的短双歧杆菌。
9.权利要求1或2的组合物,包含5-16en.%蛋白质,30-60en.%脂肪,和25-75en.%碳水化合物。
10.权利要求1或2的组合物,包含至少5mg糖A每100ml和/或至少5mg糖B每100ml。
11.权利要求1或2的组合物,包含至少0.75mg核苷酸每100ml。
12.包含5-16en.%蛋白质、30-60en.%脂肪以及25-75en.%碳水化合物的组合物,其中包含短双歧杆菌和副干酪乳杆菌。
13.前述任意权利要求的组合物制备用于为婴儿提供营养的方法中的营养组合物的用途,所述方法包括将所述营养组合物给药婴儿。
14.权利要求1-12之一的组合物在制备组合物中的用途,所述组合物用于将在用非母乳或部分母乳喂养的婴儿的胃肠道中的双歧杆菌和/或乳杆菌种类群体正常化到母乳喂养的婴儿中的双歧杆菌和/或乳杆菌种类群体。
15.权利要求1-12之一的组合物在制备用于预防和/或治疗胃肠疾病、免疫疾病和/或内分泌疾病的组合物中的用途。
16.权利要求15的用途,其中所述疾病选自以下疾病组成的组:过敏症,感染,过敏性鼻炎,食物超敏反应,异位性皮炎,湿疹,哮喘,腹泻,病毒性腹泻,肠道炎症,便秘,肠痉挛,绞痛,幼儿肥胖症和糖尿病。
17.权利要求1-12之一的组合物在制备用于预防和/或治疗过敏,异位性皮炎,湿疹和/或感染的组合物中的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05075486.0 | 2005-02-28 | ||
EP05075486 | 2005-02-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800063682A Division CN101128129A (zh) | 2005-02-28 | 2006-02-28 | 具有益生菌的营养组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104223094A true CN104223094A (zh) | 2014-12-24 |
Family
ID=35229644
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800063682A Pending CN101128129A (zh) | 2005-02-28 | 2006-02-28 | 具有益生菌的营养组合物 |
CN201410366993.4A Pending CN104223094A (zh) | 2005-02-28 | 2006-02-28 | 具有益生菌的营养组合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800063682A Pending CN101128129A (zh) | 2005-02-28 | 2006-02-28 | 具有益生菌的营养组合物 |
Country Status (16)
Country | Link |
---|---|
US (3) | US9314047B2 (zh) |
EP (3) | EP2351492B1 (zh) |
CN (2) | CN101128129A (zh) |
AT (1) | ATE526836T1 (zh) |
AU (1) | AU2006217160B2 (zh) |
BR (1) | BRPI0607743B1 (zh) |
CA (1) | CA2598961C (zh) |
DK (2) | DK2351492T3 (zh) |
ES (3) | ES2702631T5 (zh) |
MX (1) | MX2007010466A (zh) |
PL (3) | PL1855550T3 (zh) |
PT (2) | PT1855550E (zh) |
RU (2) | RU2422025C2 (zh) |
TR (1) | TR201820329T4 (zh) |
WO (1) | WO2006091103A2 (zh) |
ZA (1) | ZA200706875B (zh) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006012536A2 (en) | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
EP1776877A1 (en) | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
WO2008054192A1 (en) * | 2006-11-02 | 2008-05-08 | N.V. Nutricia | Use of nutritional compositions for preventing disorders |
US20110136732A1 (en) | 2005-12-23 | 2011-06-09 | N.V. Nutricia | Infant nutritional compositions for preventing obesity |
DK1800675T3 (da) | 2005-12-23 | 2011-09-05 | Nutricia Nv | Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens |
JP2009067679A (ja) * | 2005-12-27 | 2009-04-02 | Univ Of Tokushima | 抗ヒスタミン作用を有する医薬 |
BRPI0721827B8 (pt) * | 2006-08-04 | 2021-05-25 | Shs Int Ltd | uso de uma composição, e, composição |
US20080254166A1 (en) * | 2007-01-25 | 2008-10-16 | Potter Susan M | Food Additives Containing Combinations of Prebiotics and Probiotics |
CN101668437A (zh) | 2007-03-13 | 2010-03-10 | N.V.努特里奇亚 | 使用含有非消化性糖的组合物改善能力的方法 |
EP1974734A1 (en) * | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics for reduction of risk of obesity |
WO2008153377A1 (en) | 2007-06-15 | 2008-12-18 | N.V. Nutricia | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
WO2008156354A1 (en) * | 2007-06-21 | 2008-12-24 | N.V. Nutricia | Modulation of intestinal flora of hiv patients |
JP2010531840A (ja) * | 2007-06-27 | 2010-09-30 | セーホーエル.ハンセン アクティーゼルスカブ | アトピー性皮膚炎の治療のためのラクトバチルス・ヘルベティカス菌組成物 |
EP2011506A1 (en) | 2007-07-05 | 2009-01-07 | Nestec S.A. | Supplementation of maternal diet |
PT2173196E (pt) * | 2007-07-06 | 2011-05-23 | Nutricia Nv | Uso de probi?ticos e fibras para a diarreia |
JP2009057346A (ja) * | 2007-09-03 | 2009-03-19 | Kirin Holdings Co Ltd | 免疫バランス調節用組成物 |
EP2185931B1 (en) | 2007-09-07 | 2013-07-10 | Children's Hospital Medical Center | Use of secretor, lewis and sialyl antigen levels as predictors for disease |
DK2190304T3 (da) * | 2007-09-17 | 2012-03-12 | Nutricia Nv | Ernæringsformulering med højt energiindhold |
WO2009067000A1 (en) * | 2007-11-20 | 2009-05-28 | N.V. Nutricia | Composition with synbiotics |
WO2009072889A1 (en) * | 2007-12-07 | 2009-06-11 | N.V. Nutricia | Bifidobacterium for dust mite allergy |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
EP2589302B1 (en) * | 2007-12-21 | 2016-11-23 | N.V. Nutricia | Use of sphingomyelin and non-digestible carbohydrates for improving intestinal microbiota |
EP2123168B1 (en) * | 2008-05-16 | 2011-12-21 | Nestec S.A. | Lactobacillus paracasei and weight control |
EP2143341A1 (en) * | 2008-07-08 | 2010-01-13 | Nestec S.A. | Nutritional Composition Containing Oligosaccharide Mixture |
US20110097437A1 (en) * | 2008-06-13 | 2011-04-28 | N.V. Nutricia | Nutrition for prevention of infections |
WO2010002241A1 (en) * | 2008-06-30 | 2010-01-07 | N.V. Nutricia | Nutritional composition for infants delivered via caesarean section |
CN101768559B (zh) * | 2008-12-31 | 2012-03-07 | 生展生物科技股份有限公司 | 副干酪乳杆菌副干酪亚种菌株及其抑菌组合物和用途 |
BRPI1008280A2 (pt) | 2009-02-24 | 2015-08-25 | Ritter Pharmaceuticals Inc | Formulações prebióticas e métodos mde uso |
RU2556124C2 (ru) * | 2009-05-11 | 2015-07-10 | Нестек С.А. | Lactobacillus johnsonii La1 NСС533 (CNCM 1-1225) И ИММУННЫЕ НАРУШЕНИЯ |
EP2251021B1 (en) * | 2009-05-11 | 2012-02-22 | Nestec S.A. | Prevention and treatment of allergic diarrhoea |
ITMI20091034A1 (it) * | 2009-06-11 | 2010-12-12 | Parmalat Spa | Specie probiotica di bifidobacterium breve |
PL2808024T3 (pl) * | 2009-06-19 | 2019-09-30 | Dupont Nutrition Biosciences Aps | Bifidobakterie do leczenia zastoinowej niewydolności serca |
EP2451462B1 (en) | 2009-07-06 | 2017-09-06 | Children's Hospital Medical Center | Inhibiting inflammation with milk oligosaccharides |
BR112012002223A2 (pt) * | 2009-07-31 | 2016-06-07 | Nestec Sa | composição nutricional para lactentes ou animais de estimação com probióticos e nutrientes selecionados |
WO2011034166A1 (ja) * | 2009-09-17 | 2011-03-24 | 森永乳業株式会社 | 抗肥満剤、抗肥満用飲食品、耐糖能改善剤及び耐糖能改善用飲食品 |
EP2308498A1 (en) * | 2009-09-30 | 2011-04-13 | Nestec S.A. | Administration of Bifidobacterium breve during infancy to prevent inflammation later in life |
WO2011071367A1 (en) * | 2009-12-11 | 2011-06-16 | N.V. Nutricia | Metabolic imprinting effects of structured lipids |
FR2955774A1 (fr) | 2010-02-02 | 2011-08-05 | Aragan | Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation |
EP2563372A4 (en) | 2010-04-28 | 2013-10-02 | Ritter Pharmaceuticals Inc | PREBIOTIC FORMULATIONS AND METHODS OF USE |
WO2011149335A1 (en) * | 2010-05-25 | 2011-12-01 | N.V. Nutricia | Immune imprinting nutritional composition |
IT1405395B1 (it) * | 2010-08-05 | 2014-01-10 | Proge Farm Srl | Composizioni di probiotici e oli e loro uso. |
ITMI20110793A1 (it) * | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati. |
ITMI20110792A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia. |
ITMI20110791A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri in grado di metabolizzare gli ossalati. |
US10039296B2 (en) | 2011-06-20 | 2018-08-07 | H.J. Heinz Company Brands Llc | Probiotic compositions and methods |
WO2013004815A1 (en) * | 2011-07-06 | 2013-01-10 | Dupont Nutrition Biosciences Aps | Method for reducing the viscosity of a microorganism-containing suspension or concentrate |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
ITMI20111718A1 (it) | 2011-09-23 | 2013-03-24 | Probiotical Spa | Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali. |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
FI20116008A0 (fi) * | 2011-10-12 | 2011-10-12 | Maeyrae Maekinen Annika | Viskeraalisen rasvan estäminen ja diagnostisointi |
WO2013187755A1 (en) | 2012-06-14 | 2013-12-19 | N.V. Nutricia | Fermented infant formula with non digestible oligosaccharides |
CA3092314A1 (en) * | 2012-09-20 | 2014-03-27 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
ES2884223T3 (es) * | 2012-11-02 | 2021-12-10 | Nutricia Nv | Combinación de simbióticos para la mejora del cerebro |
US10626460B2 (en) | 2013-02-21 | 2020-04-21 | Children's Hospital Medical Center | Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
US20140328970A1 (en) * | 2013-05-03 | 2014-11-06 | Mead Johnson Nutrition Company | Nutritional Composition Comprising Whey and Hydrolyzed Casein and Uses Thereof |
DK2994150T3 (da) | 2013-05-10 | 2019-06-11 | Heinz Co Brands H J Llc | Probiotika og fremgangsmåde til anvendelse |
ITMI20130793A1 (it) | 2013-05-14 | 2014-11-15 | Probiotical Spa | Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti. |
WO2016013928A1 (en) | 2014-07-24 | 2016-01-28 | N.V. Nutricia | Prevention or treatment of food allergy in infants and toddlers |
MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
HUE037476T2 (hu) | 2014-12-23 | 2018-08-28 | 4D Pharma Res Ltd | Pirin polipeptid és immunmodulálás |
LT3065748T (lt) | 2014-12-23 | 2018-03-12 | 4D Pharma Research Limited | Bacteroides thetaiotaomicron padermė ir jos panaudojimas uždegimo sumažinimui |
US10857167B2 (en) | 2015-04-28 | 2020-12-08 | Children's Hospital Medical Center | Use of oligosaccharide compositions to enhance weight gain |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
LT3650033T (lt) | 2015-06-15 | 2022-04-11 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterinius kamienus |
RS59308B1 (sr) | 2015-06-15 | 2019-10-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
EP3636272A1 (en) | 2015-06-15 | 2020-04-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
GB2561748B (en) | 2015-11-20 | 2019-05-08 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
TW201733601A (zh) | 2016-03-04 | 2017-10-01 | 4D製藥有限公司 | 包含細菌菌株之組合物 |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
RU2748279C2 (ru) * | 2016-08-04 | 2021-05-21 | Сосьете Де Продюи Нестле С.А. | Питательные композиции и детские смеси, содержащие смесь олигосахаридов и необязательно bifidobacterium lactis для профилактики, лечения или снижения степени тяжести диареи, не связанной с ротавирусом |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
MA48940A (fr) | 2017-05-22 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
MD3638271T2 (ro) | 2017-06-14 | 2021-03-31 | 4D Pharma Res Ltd | Compoziții cuprizând tulpini bacteriene |
DK3804737T3 (da) | 2017-06-14 | 2022-07-25 | 4D Pharma Res Ltd | Sammensætninger omfattende bakteriestammer |
CN110831609A (zh) * | 2017-06-30 | 2020-02-21 | N·V·努特里奇亚 | 用于预防代谢紊乱的合生素组合物 |
EP3645023B1 (en) | 2017-06-30 | 2022-09-14 | N.V. Nutricia | Synbiotic composition for preventing hyperinsulinemia and insulin resistance |
CN111698993A (zh) * | 2018-02-09 | 2020-09-22 | N·V·努特里奇亚 | 含有不可消化寡糖的发酵配方物 |
JP7266580B2 (ja) * | 2018-03-23 | 2023-04-28 | 森永乳業株式会社 | 学童期以降の高血糖に起因する疾患の予防のための乳幼児用組成物 |
WO2022112927A1 (en) * | 2020-11-24 | 2022-06-02 | Johnson & Johnson Consumer Inc. | Methods of preventing, delaying or ameliorating atopic diseases |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1383727A (zh) * | 2001-04-29 | 2002-12-11 | 上海光明乳业股份有限公司 | 益菌奶及其制造方法 |
EP1364586A1 (en) * | 2002-05-24 | 2003-11-26 | Nestec S.A. | Probiotics and oral tolerance |
CN1465261A (zh) * | 2002-11-13 | 2004-01-07 | 上海光明乳业股份有限公司 | 免疫配方奶粉及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN881396A0 (en) | 1996-03-20 | 1996-04-18 | Arnott's Biscuits Limited | Enhancement of microbial colonization of the gastrointestinal tract |
JP4008974B2 (ja) | 1996-12-12 | 2007-11-14 | 森永乳業株式会社 | ビフィズス菌増殖促進組成物及びその用途 |
CN1269724A (zh) * | 1997-07-05 | 2000-10-11 | 雀巢制品公司 | 矿物质通过肠细胞的吸收 |
DE19836339B4 (de) | 1998-08-11 | 2011-12-22 | N.V. Nutricia | Kohlenhydratmischung |
NL1010770C2 (nl) * | 1998-12-09 | 2000-06-13 | Nutricia Nv | Preparaat dat oligosacchariden en probiotica bevat. |
EP1175905A1 (en) * | 2000-07-24 | 2002-01-30 | Societe Des Produits Nestle S.A. | Nutritional Composition |
US6592863B2 (en) * | 2000-08-22 | 2003-07-15 | Nestec S.A. | Nutritional composition |
FI109602B (fi) * | 2001-01-25 | 2002-09-13 | Valio Oy | Probioottiyhdistelmä |
DE10206995B4 (de) * | 2002-02-19 | 2014-01-02 | Orthomol Pharmazeutische Vertriebs Gmbh | Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika |
ITMI20020399A1 (it) * | 2002-02-28 | 2003-08-28 | Ct Sperimentale Del Latte S P | Composizioni dietetiche e/o farmaceutiche per uso umano e/o animale abase di preparati microbici probiotici |
EP1374878A1 (en) * | 2002-06-20 | 2004-01-02 | N.V. Nutricia | Method and composition for preventing or alleviating symptoms of malabsorption from the gastrointestinal tract |
EP1384483A1 (en) * | 2002-07-23 | 2004-01-28 | Nestec S.A. | Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function |
EP1481681A1 (en) * | 2003-05-30 | 2004-12-01 | Claudio De Simone | Lactic acid bacteria combination and compositions thereof |
NZ546664A (en) * | 2003-10-24 | 2009-04-30 | Nutricia Nv | Synbiotic composition for infants |
-
2006
- 2006-02-28 EP EP11162630.5A patent/EP2351492B1/en active Active
- 2006-02-28 ES ES14181368T patent/ES2702631T5/es active Active
- 2006-02-28 DK DK11162630.5T patent/DK2351492T3/en active
- 2006-02-28 AU AU2006217160A patent/AU2006217160B2/en active Active
- 2006-02-28 PL PL06716673T patent/PL1855550T3/pl unknown
- 2006-02-28 PL PL11162630T patent/PL2351492T3/pl unknown
- 2006-02-28 ES ES11162630.5T patent/ES2524344T3/es active Active
- 2006-02-28 CN CNA2006800063682A patent/CN101128129A/zh active Pending
- 2006-02-28 TR TR2018/20329T patent/TR201820329T4/tr unknown
- 2006-02-28 AT AT06716673T patent/ATE526836T1/de active
- 2006-02-28 PT PT06716673T patent/PT1855550E/pt unknown
- 2006-02-28 EP EP14181368.3A patent/EP2805625B2/en active Active
- 2006-02-28 MX MX2007010466A patent/MX2007010466A/es active IP Right Grant
- 2006-02-28 US US11/817,102 patent/US9314047B2/en active Active
- 2006-02-28 PL PL14181368.3T patent/PL2805625T5/pl unknown
- 2006-02-28 RU RU2007135869/10A patent/RU2422025C2/ru active
- 2006-02-28 US US11/364,963 patent/US20060194241A1/en not_active Abandoned
- 2006-02-28 ES ES06716673T patent/ES2373971T3/es active Active
- 2006-02-28 CN CN201410366993.4A patent/CN104223094A/zh active Pending
- 2006-02-28 WO PCT/NL2006/050040 patent/WO2006091103A2/en active Search and Examination
- 2006-02-28 DK DK06716673.6T patent/DK1855550T3/da active
- 2006-02-28 BR BRPI0607743-9A patent/BRPI0607743B1/pt active IP Right Grant
- 2006-02-28 EP EP06716673A patent/EP1855550B1/en active Active
- 2006-02-28 PT PT111626305T patent/PT2351492E/pt unknown
- 2006-02-28 CA CA2598961A patent/CA2598961C/en active Active
-
2007
- 2007-08-16 ZA ZA200706875A patent/ZA200706875B/xx unknown
-
2011
- 2011-03-16 RU RU2011110056/10A patent/RU2595396C2/ru active
-
2016
- 2016-04-01 US US15/088,639 patent/US10071125B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1383727A (zh) * | 2001-04-29 | 2002-12-11 | 上海光明乳业股份有限公司 | 益菌奶及其制造方法 |
EP1364586A1 (en) * | 2002-05-24 | 2003-11-26 | Nestec S.A. | Probiotics and oral tolerance |
CN1465261A (zh) * | 2002-11-13 | 2004-01-07 | 上海光明乳业股份有限公司 | 免疫配方奶粉及其制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104223094A (zh) | 具有益生菌的营养组合物 | |
RU2456008C2 (ru) | Синбиотик для улучшения кишечной микробиоты | |
US20080199446A1 (en) | Uronic Acid and Probiotics | |
TW201002216A (en) | Probiotics to improve gut microbiota | |
CN101801220A (zh) | 含有非活的双歧杆菌和非消化性寡糖的营养物 | |
TW201233334A (en) | Human milk oligosaccharides to promote growth of beneficial bacteria | |
EP3071208A1 (en) | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children | |
MX2008011450A (es) | Mezcla simbiotica. | |
AU2022203298B2 (en) | Nutritional compositions and infant formulas comprising a mix of oligosaccharides and optionally bifidobacterium lactis for preventing, treating or reducing the severity of non-rota virus-associated diarrhoea | |
EP2127661A1 (en) | Probiotics to improve gut microbiotica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141224 |